Pilot Study on Metformin A National Institutes of Health program project grant on Fanconi anemia (FA) led by Dr. Markus Grompe at Oregon Health & Science University identified that metformin (a drug approved by the FDA to treat type II...
Announcements
Fanconi anemia (FA) is a hereditary disorder with a high predisposition to cancer, especially leukemia and squamous cell carcinoma (SCC). Head and neck squamous cell carcinoma (HNSCC) is the most common SCC diagnosed in people with FA. Diagnosis typically occurs...
Announcements
The David B. Frohnmayer Early Investigator Award was inaugurated in 2015, months after FARF co-founder Dave Frohnmayer passed away. One of his most salient leadership traits was his ability to recognize talent in others and inspire them to solve important...
Announcements
Mutations in 23 Fanconi anemia (FA) genes cause defects in DNA repair, which leads to chromosome instability, bone marrow failure, malformations, and susceptibility to cancer. The most well-described role of FA genes in DNA repair is known as the “canonical”...
Announcements
What motivates me to work on FA: The patients and the families; that is clear for me. When I was an undergraduate student, I realized that I would like to work in genetic engineering to correct inherited disorders, but I...
Announcements
New approaches are needed for both prevention and treatment of squamous cell carcinoma (SCC) in patients with FA - approaches that have fewer and less severe side effects than chemotherapy and radiation therapy. The purpose of this Phase 2 study...
Announcements
